Pilot prognostic model of extremely poor survival among high-risk hepatocellular carcinoma patients

Cancer

Volumn 118, Issue 24, 2012, Pages 6118-6125

  Wray, Curtis J ^a   Harvin, John A ^a   Silberfein, Eric J ^b   Ko, Tien C ^a   Kao, Lillian S ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

cirrhosis; health care disparities; hepatocellular carcinoma; prognostic models; survival

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CREATININE;

ADULT; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SURVIVAL TIME;

CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MEDICALLY UNDERSERVED AREA; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84870707741     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27649     Document Type: Review

References (35)

1. Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010; 44: 239-245.
2. Centers for Disease Control and Prevention (CDC) Hepatocellular carcinoma-United States, 2001-2006. MMWR Morb Mortal Weekly Rep. 2010; 59: 517-520.
3. El-Serag HB,. Hepatocellular carcinoma. N Engl J Med. 2011; 365: 1118-1127.
4. El-Serag HB,. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002; 36 (5 suppl 1): S74-S783.
5. Hussain K, El-Serag HB,. Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2009; 55: 123-138.
6. Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010; 116: 1367-1377.
7. US Department of Health and Human Services. Medically Underserved Areas and Populations (MUA/Ps). Guidelines for MUA and MUP Designation. Available at: http://bhpr.hrsa.gov/shortage/muaps/. Accessed February 23, 2012.
8. Harvin JA, Van Buren G, Tsao K, Cen P, Ko TC, Wray CJ,. Hepatocellular carcinoma survival in uninsured and underinsured patients. J Surg Res. 2011; 166: 189-193.
9. Mallett S, Royston P, Dutton S, Waters R, Altman DG,. Reporting methods in studies developing prognostic models in cancer: a review [serial online]. BMC Med. 2010; 8: 20.
10. Riley RD, Sauerbrei W, Altman DG,. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer. 2009; 100: 1219-1229.
11. Stone P, Kelly L, Head R, White S,. Development and validation of a prognostic scale for use in patients with advanced cancer. Palliat Med. 2008; 22: 711-717.
12. Ohno-Machado L,. Modeling medical prognosis: survival analysis techniques. J Biomed Inform. 2001; 34: 428-439.
13. Schumacher M, Graf E, Gerds T,. How to assess prognostic models for survival data: a case study in oncology. Methods Inf Med. 2003; 42: 564-571.
14. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991; 100: 1619-1636.
15. Siro CA, Bastos PG, Knaus WA, Wagner DP,. APACHE II scores in the prediction of multiple organ failure syndrome. Arch Surg. 1991; 126: 528-529.
16. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33: 464-470.
17. Kohn L,. To err is human: an interview with the Institute of Medicine's Linda Kohn. Jt Comm J Qual Improv. 2000; 26: 227-234.
18. Kohn LT,. Organizing and managing care in a changing health system. Health Serv Res. 2000; 35 (1 pt 1): 37-52.
19. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD,. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 2000; 19: 1059-1079.
20. Harrell WA, Spaulding LM,. Social psychological models of choice behavior and drivers' left turns. J Soc Psychol. 2001; 141: 714-722.
21. Royston P, Moons KG, Altman DG, Vergouwe Y,. Prognosis and prognostic research: developing a prognostic model [serial online]. BMJ. 2009; 338: b604.
22. Newson RB,. Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J. 2010; 10: 339-358.
23. Royston P, Sauerbrei W,. A new measure of prognostic separation in survival data. Stat Med. 2004; 23: 723-748.
24. Newson R,. Confidence intervals for rank statistics: Somers' D and extensions. Stata J. 2006; 6: 309-334.
25. Pepe MS, Longton G, Janes H,. Estimation and comparison of receiver operating characteristic curves. Stata J. 2009; 9: 1-16.
26. Cummings P,. Estimating adjusted risk ratios for matched and unmatched data: an update. Stata J. 2011; 11: 290-298.
27. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001; 7: 567-580.
28. Brown DB, Fundakowski CE, Lisker-Melman M, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2004; 15: 1209-1218.
29. Soga K, Tomikashi K, Miyawaki K, et al. MELD score, Child-Pugh score, and decreased albumin as risk factors for gastric variceal bleeding. Hepatogastroenterology. 2009; 56: 1552-1556.
30. Telem DA, Schiano T, Goldstone R, et al. Factors that predict outcome of abdominal operations in patients with advanced cirrhosis. Clin Gastroenterol Hepatol. 2010; 8: 451-457; quiz e58.
31. Hosmer DW, Lemeshow S, May S,. Applied Survival Analysis: Regression Modeling of Time-To-Event Data. 2nd ed. Hoboken, NJ: Wiley-Interscience; 2008.
32. The AM, Hak T, Koeter G, van Der Wal G,. Collusion in doctor-patient communication about imminent death: an ethnographic study. BMJ. 2000; 321: 1376-1381.
33. Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ. 2003; 327: 195-198.
34. Lamont EB, Christakis NA,. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med. 2001; 134: 1096-1105.
35. Schwartz JM, Ham JM,. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol. 2003; 6: 465-472.